Integrating Fat Embolism Syndrome Scoring Indices in Sickle Cell Disease: A Practice Management Review

2017 ◽  
Vol 34 (10) ◽  
pp. 797-804 ◽  
Author(s):  
Keneisha Bailey ◽  
Jagila Wesley ◽  
Adebayo Adeyinka ◽  
Louisdon Pierre

Fat embolism syndrome (FES) has been described in the literature as a rare complication of sickle cell disease (SCD). A review article published in 2005 reported 24 cases of FES associated with SCD. In many cases, a definitive diagnosis of FES in SCD is made on autopsy because of the lack of early recognition and the paucity of sensitive and specific testing for this syndrome. Patients with FES usually have a fulminant, rapidly deteriorating clinical course with mortality occurring within the first 24 hours. We postulate that FES is not well recognized in SCD and that FES scores are useful diagnostic tools in patients with SCD. We queried the electronic medical records with the diagnostic codes for SCD with acute chest syndrome (ACS), pulmonary embolism, or acute respiratory distress syndrome admitted to our hospital from 2008 to 2016 to identify patients suspected of having FES. In addition, we performed an extensive literature review to evaluate the management practice of pediatric patients with FES and SCD from 1966 to 2016. Six patients met our selection criteria from the hospital records, and 4 case reports from the literature search were also included. We applied the Gurd and Wilson criteria and the Schonfeld Fat Embolism Index to identify patients who met the criteria for FES. Nine patients fulfilled Gurd and Wilson criteria, and 9 patients who were evaluable met the Schonfeld criteria for FES. A rapidly deteriorating clinical course in a patient with SCD presenting with ACS or severe vaso-occlusive crisis should trigger a high index of suspicion for FES. Gurd and Wilson criteria or the Schonfeld Fat Embolism Index are useful diagnostic tools for FES in SCD.

2019 ◽  
Vol 14 ◽  
pp. 19-20 ◽  
Author(s):  
Cody L. Nathan ◽  
Whitley W. Aamodt ◽  
Tanuja Yalamarti ◽  
Calli Dogon ◽  
Paul Kinniry

2016 ◽  
Vol 5 (1) ◽  
pp. 39-43 ◽  
Author(s):  
Paul Greaves ◽  
Vivek Mathew ◽  
Catherine Peters ◽  
Susan Rowe ◽  
Roger J. Amos ◽  
...  

2017 ◽  
Vol 7 (4) ◽  
pp. 42-50 ◽  
Author(s):  
Eduardo Pelegrineti Targueta ◽  
André Carramenha de Góes Hirano ◽  
Fernando Peixoto Ferraz de Campos ◽  
João Augusto dos Santos Martines ◽  
Silvana Maria Lovisolo ◽  
...  

2018 ◽  
Vol 8 (2) ◽  
pp. 162-164 ◽  
Author(s):  
Jennifer H. Kang ◽  
Charles William Hargett ◽  
Theresa Sevilis ◽  
Matthew Luedke

Blood ◽  
1996 ◽  
Vol 87 (6) ◽  
pp. 2573-2578 ◽  
Author(s):  
LA Styles ◽  
CG Schalkwijk ◽  
AJ Aarsman ◽  
EP Vichinsky ◽  
BH Lubin ◽  
...  

Acute chest syndrome (ACS) is associated with significant morbidity and is the leading cause of death in patients with sickle cell disease (SCD). Recent reports suggest that bone marrow fat embolism can be detected in many cases of severe ACS. Secretory phospholipase A2 (sPLA2) is an important inflammatory mediator and liberates free fatty acids, which are felt to be responsible for the acute lung injury of the fat embolism syndrome. We measured SPLA2 levels in 35 SCD patients during 20 admissions for ACS, 10 admissions for vaso-occlusive crisis, and during 12 clinic visits when patients were at the steady state. Eleven non-SCD patients with pneumonia were also evaluated. To determine if there was a relationship between sPLA2 and the severity of ACS we correlated SPLA2 levels with the clinical course of the patient. In comparison with normal controls (mean = 3.1 +/- 1.1 ng/mL), the non- SCD patients with pneumonia (mean = 68.6 +/- 82.9 ng/mL) and all three SCD patient groups had an elevation of SPLA2 (steady state mean = 10.0 +/- 8.4 ng/mL; vaso-occlusive crisis mean = 23.7 +/- 40.5 ng/mL; ACS mean = 336 +/- 209 ng/mL). In patients with ACS sPLA2 levels were 100- fold greater than normal control values, 35 times greater than values in SCD patients at baseline, and five times greater than non-SCD patients with pneumonia. The degree of SPLA2 elevation in ACS correlated with three different measures of clinical severity and, in patients followed sequentially, the rise in SPLA2 coincided with the onset of ACS. The dramatic elevation of SPLA2 in patients with ACS but not in patients with vaso-occlusive crisis or non-SCD patients with pneumonia and the correlation between levels of SPLA2 and clinical severity suggest a role for SPLA2 in the diagnosis and, perhaps, in the pathophysiology of patients with ACS.


2019 ◽  
Vol 214 ◽  
pp. 236
Author(s):  
Arielle Maroni ◽  
Stéphane Dauger ◽  
Maryline Chomton

Transfusion ◽  
2021 ◽  
Author(s):  
Mohammad Barouqa ◽  
James Szymanski ◽  
Randin Nelson ◽  
Sebastian Jofre ◽  
Monika Paroder

Sign in / Sign up

Export Citation Format

Share Document